FDA warned Disinfect & Shield that its non-alcohol hand sanitizer was an unapproved drug sold with COVID-19 and long-lasting efficacy claims.
What happened
FDA reviewed the company website on May 5, 2021. It found DISINFECT™ & SHIELD HAND SANITIZER offered for sale with claims that it kills COVID-19, protects for up to 8 hours, and is effective against pathogens such as SARS, H1N1, and Ebola. FDA cited the product as an unapproved new drug and as misbranded (misleadingly labeled), including misleading “FDA Listed” and “FDA Registered” statements.
What FDA found
The hand sanitizer was sold as a new drug without FDA approval, based on website claims that it prevents or treats COVID-19 and other diseases.
section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)FDA found no adequate and well-controlled clinical studies showing the product is generally recognized as safe and effective for its claimed uses.
section 201(p) of the FD&C Act, 21 U.S.C. § 321(p)The product's labeling claimed specific disease kill and up to 8-hour protection beyond the allowed over-the-counter antiseptic uses, so it did not meet the conditions for marketing under section 505G.
section 505G(a)(3) of the FD&C Act, 21 U.S.C. § 355h(a)(3)The website used “FDA Listed” with FDA's logo and “FDA Registered” in a way that falsely suggested FDA approval or endorsement.
section 502(a) of the FD&C Act, 21 U.S.C. § 352(a); 21 CFR 207.77(a)The product was misbranded because it was subject to section 505G but did not meet that section's marketing requirements and had no approved application.
section 502(ee) of the FD&C Act, 21 U.S.C. § 352(ee)
What FDA wants
FDA tells the company to take immediate action to stop selling unapproved products for COVID-19 and to review websites, labels, and promotional materials. Within 48 hours, the company must email FDA describing steps taken, how it will prevent recurrence, and related documentation.
Who should pay attention
- hand sanitizer brands and marketers
- online retailers and marketplaces selling OTC antiseptics
- companies making COVID-19 or antiviral claims for topical products
This is a summary. Read the original letter on fda.gov.